(주)셀렉스라이프사이언스

News

ILIAS is the Leader of Next-Generation Exosome Therapeutics.

[ENG] 보도자료

ILIAS Biologics Granted Key Patent for Exosome-based Drug Delivery System in the United States

페이지 정보

  • 작성자 : ILIAS Biologics
  • 작성일 : 20-07-08 09:52
  • 조회 : 411회

본문


7 Jul 2020


ILIAS Biologics Granted Key Patent for Exosome-based Drug Delivery System in the United States 


ILIAS Biologics announced today that the company has been granted a key exosome engineering patent by the United States Patent and Trademark Office (USPTO). A patent for ILIAS's exosome engineering was previously granted in South Korea by the Korean Intellectual Property Office (KIPO), and the company has applied for the patents in 7 other countries as well. This latest patent is integral to the company's EXPLOR® (EXosome engineering for Protein Loading via Optically Reversible protein–protein interaction) platform technology as well as the Exo-Target® products, as the patent covers not only EXPLOR® technology but also its application for various therapeutic cargo proteins developed by ILIAS for loading into exosomes. 

 

Press Link: https://www.prnewswire.com/news-releases/ilias-biologics-granted-key-patent-for-exosome-based-drug-delivery-system-in-the-united-states-301088742.html

개인정보취급방침

닫기

이메일주소무단수집거부

닫기

사이트맵

사이트맵

몬트리올의정서
국내이행법령
사업안내
특정물질 수출입
알림·자료실
민원서비스
닫기